Y. Adachi

Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia

Y. Ishikawa, H. Kiyoi, T. Matsushita, 2018, PloS one.

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia.

Y. Ishikawa, H. Kiyoi, Y. Adachi, 2017, Oncotarget.

Phase I clinical trial of intra‐bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation

Y. Ishikawa, Y. Kodera, Yoshiyuki Takahashi, 2020, Stem cells translational medicine.

Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells

Y. Ishikawa, Yoshiyuki Takahashi, H. Kiyoi, 2018, Medicine.

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.

T. Naoe, Y. Ishikawa, N. Fujikawa, 2018, Blood.

Mutation analysis of therapy-related myeloid neoplasms.

Y. Ishikawa, H. Kiyoi, N. Kawashima, 2018, Cancer genetics.

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.

T. Naoe, Y. Ishikawa, N. Fujikawa, 2018, Blood.